Antibody conjugate-mediated degradation represents a cutting-edge approach to targeted protein degradation. By coupling antibodies specific to cell surface proteins with molecules that induce degradation, this technique enables precise elimination of disease-causing proteins within cells. Offering a potent and highly specific therapeutic strategy, antibody conjugate-mediated degradation holds promise for treating a wide range of diseases with aberrant protein expression, including cancer and neurodegenerative disorders.
Advantages of Choosing LifeSensors for your PROTAC Drug Discovery
- Study PROTAC mediated Ubiquitination and Degradation simultaneously
- Complete suite of validation studies to establish binding, ternary complex formation, and cellular degradation
- Experience with novel E3 ligases – ~30 E3 ligases amenable to PROTAC discovery
- Proteomics to characterize protein degradation – establish selectivity
With deep and diverse expertise in medicinal chemistry, biochemistry, and cell-biology specializing in ubiquitin based drug discovery for the last 15 years, LifeSensors is proud to offer efficient methods to accelerate your discovery of novel molecules facilitating targeted protein degradation. We offer our degrader discovery services starting from design and synthesis of novel PROTACs, to monitoring PROTAC binding to target and E3 ligases (biochemical and biophysical), including functional ubiquitination and degradation assays in cells. PROTAC-mediated ubiquitylation in vitro permits rapid screening of compound libraries and allows simplification of the medicinal chemistry approach to rationally design potent molecules. Your biochemists can focus on new PROTAC targets as LifeSensors will translate its core technologies for in vitro and cellular PROTAC screens.